Vnitr Lek 2019, 65(9):553-563 | DOI: 10.36290/vnl.2019.096

Pangenotypic treatment regimens for chronic hepatitis C

Petr Urbánek
Interní klinika 1. LF UK a ÚVN - Vojenská fakultní nemocnice Praha

The treatment of chronic hepatitis C is currently based exclusively on the use of drugs from the direct-acting antiviral class. They are substances that inhibit one of the 3 most important enzymes of the virus replication cycle. Antiviral drugs are divided according to the target structure into 3 basic classes, further division is mainly based on the chemical structure of individual antivirals. A common feature of all the regimens is high efficiency and safety. Pangenotypic efficacy regimens are those that utilize a combination of 2 or 3 antiviral agents of different classes, and are effective for all HCV genotypes. Currently there are 3 such regimens available. Pangenotypic regimens probably represent the latest stage of development of treatment for chronic hepatitis C. The review discusses in detail the efficiency of different pangenotypic regimens in individual subgroups of patients with HCV infection. Attention is primarily paid to the data bases for their use.

Keywords: antiviral agent; chronic hepatitis C; treatment

Received: January 8, 2018; Accepted: April 17, 2019; Published: September 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánek P. Pangenotypic treatment regimens for chronic hepatitis C. Vnitr Lek. 2019;65(9):553-563. doi: 10.36290/vnl.2019.096.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. [World Health organization]. Global alert and response (GAR). Hepatitis C. 2012. Dostupné z WWW: <http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4html>.
    2. Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4): 529-538. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2006.05.013>. Go to original source... Go to PubMed...
    3. Kanwal F, Hoang T, Kramer JR et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140(4): 1182-1188.e1. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2010.12.032>. Go to original source... Go to PubMed...
    4. Deuffic-Burban S, Poynard T, Sulkowski MS et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14(2): 107-115. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2893.2006.00785.x>. Go to original source... Go to PubMed...
    5. Urbánek P, Husa P, Galský J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Čas Lék. Česk 2008; 147(5): 1-12.
    6. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa020047>. Go to original source... Go to PubMed...
    7. Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140(5): 346-355. Dostupné z DOI: <http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00010>. Go to original source... Go to PubMed...
    8. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 69(2): 461-511. Dostupné z DOI: <https://doi.org/10.1016/j.jhep.2018.03.026>. Go to original source... Go to PubMed...
    9. Epclusa. SPC. Datum první registrace: 6. července 2016, datum poslední revize textu: červenec 2016. Dostupné z WWW: <www.sukl.cz>.
    10. Younossi ZM, Stepanova M, Feld J et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol 2016; 65(1): 33-39. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2016.02.042>. Go to original source... Go to PubMed...
    11. Younossi ZM, Stepanova M, Sulkowski M et al. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results from Astral-2 and -3 Clinical Trials. Clin Infect Dis 2016; 63(8): 1042-1048. Dostupné z DOI: <http://dx.doi.org/10.1093/cid/ciw496>. Go to original source... Go to PubMed...
    12. Foster GR, Afdhal N, Roberts SK et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015; 373(27): 2608-2617. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1512612>. Go to original source... Go to PubMed...
    13. Curry MP, O'Leary JG, Bzowej N et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015; 373(27): 2618-2628. <http://dx.doi.org/10.1056/NEJMoa1512614>. Go to original source... Go to PubMed...
    14. Maviret. SPC. Datum první registrace: 26. 7. 2017, datum poslední revize textu: listopad 2018. Dostupné z WWW: <http://www.sukl.cz/modules/medication/detail.php?code=0222376&tab=texts>.
    15. Zeuzem S, Foster GR, Wang S et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med 2018; 378(4): 354-369. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1702417>. Go to original source... Go to PubMed...
    16. Asselah T, Kowdley KV, Zadeikis N et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol 2018; 16(3): 417-426. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2017.09.027>. Go to original source... Go to PubMed...
    17. Forns X, Lee SS, Valdes J et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 201; 17(10): 1062-1068. Dostupné z DOI: <http://dx.doi.org/10.1016/S1473-3099(17)30496-6>. Go to original source... Go to PubMed...
    18. Brown RS Jr, Hezode C, Wang S et al. Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis: the EXPEDITION-8 study [AASLD abstract LB-7]. Hepatology 2018; 68(Suppl 1). Dostupné z WWW: <https://www.sciencedirect.com/journal/journal-of-hepatology/vol/68/suppl/S1>. Go to original source...
    19. Wyles D, Poordad F, Wang S et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology 2017; 67(2):514-523. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.29541>. Go to original source... Go to PubMed...
    20. Kwo PY, Poordad F, Asatryan A et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 2017; 67(2): 263-271. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2017.03.039>. Go to original source... Go to PubMed...
    21. Vosevi. SPC. Datum první registrace: 26. července 2017, datum poslední revize textu: listopad 2018. Dostupné z WWW: <http://www.sukl.cz/modules/medication/detail.php?code=0222375&tab=texts>.
    22. Bourlière M, Gordon SC, Flamm SL et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med 2017; 376(22): 2134-2146. Dostupné z DOI: <http://10.1056/NEJMoa1613512>. Go to original source... Go to PubMed...
    23. Jacobson IM, Lawitz E, Gane EJ et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology 2017; 153(1): 113-122. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2017.03.047>. Go to original source... Go to PubMed...
    24. Foster GR, Thompson A, Ruane PJ et al. A Randomized, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study. Hepatology 2016; 64(1 Suppl): A258. Dostupné z DOI: <https://doi.org/10.1002/hep.28796>. Go to original source... Go to PubMed...
    25. Zeuzem S, Flamm S, Tong M et al. A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1-6 HCV Infection: The POLARIS-4 Study. Hepatology 2016; 64(1 Suppl): A109. Dostupné z DOI: <https://doi.org/10.1002/hep.28796>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.